---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093307"
form_type: "8-K"
ticker: "GERN"
cik: "0000886744"
company_name: "GERON CORP"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:30:47.790058+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Geron Q2 net loss $67.4M; RYTELO launch underway with ~160 patients treated by July 31

## Summary
- Net loss of $67.4M ($0.10 per share) for Q2 2024, compared to $49.2M ($0.09) in Q2 2023.
- RYTELO (imetelstat) commercially launched June 27, 2024; estimated ~160 patients treated as of July 31, 2024.
- Total product revenue $780k for Q2; net revenue $882k (vs $29k prior year period).
- Cash and marketable securities $430.4M as of June 30, 2024; FY2024 operating expenses guided to $270M-$280M.
- NCCN Guidelines updated to include RYTELO as Category 1 for second-line and Category 2A for first-line LR-MDS treatment.

## SEC filing metadata
- accession: 0000950170-24-093307
- form_type: 8-K
- ticker: GERN
- cik: 0000886744
- company_name: GERON CORP
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886744/000095017024093307/0000950170-24-093307-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886744/000095017024093307/gern-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093307
- JSON: https://secwatch.observer/filing/0000950170-24-093307.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093307.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.